株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

認知症:パイプライン分析

Dementia - Pipeline Review, H1 2017

発行 Global Markets Direct 商品コード 245960
出版日 ページ情報 英文 219 Pages
即納可能
価格
本日の銀行送金レート: 1USD=112.05円で換算しております。
Back to Top
認知症:パイプライン分析 Dementia - Pipeline Review, H1 2017
出版日: 2017年03月15日 ページ情報: 英文 219 Pages
概要

認知症とは、思考力・記憶力・推理力といった、日常的機能にも関わる重要な精神機能が損傷した状態を指します。主な症状として、記憶喪失や妄想、興奮、人格変化、調整・運動能力の障害などが挙げられます。疾病素質には、年齢や喫煙、肥満症、高血圧、炎症、心血管疾患などがあります。

当レポートでは、世界各国での認知症治療用のパイプライン製品の開発状況について分析し、製品開発・上市の最新動向や、治験の各段階にある製品の一覧、主要企業のプロファイル、主な薬剤の概要、最新の業界動向などの情報をお届けします。

目次

イントロダクション

  • 分析範囲

認知症の概要

治療薬の開発

  • 認知症向けパイプライン製品:概要
  • 認知症向けパイプライン製品:比較分析

各企業で開発中の認知症治療薬

大学/研究機関で研究中の認知症治療薬

パイプライン製品の概略

  • 後期段階の製品
  • 治験段階の製品
  • 初期段階の製品
  • 不明確な段階にある製品

認知症治療薬:開発中の製品の一覧(企業別)

認知症治療薬:研究中の製品の一覧(大学/研究機関別)

認知症治療薬の開発に従事している企業

  • Adamas Pharmaceuticals, Inc.
  • AgeneBio Inc.
  • Alector LLC
  • AlzProtect SAS
  • Amarantus Bioscience Holdings, Inc.
  • Axon Neuroscience SE
  • Axovant Sciences Ltd.
  • BioArctic Neuroscience AB
  • Biogen, Inc.
  • Biotie Therapies Corp.
  • Boehringer Ingelheim GmbH
  • Chase Pharmaceuticals Corporation
  • Daewoong Pharmaceutical Co., Ltd.
  • エーザイ
  • FORUM Pharmaceuticals Inc.
  • H. Lundbeck A/S
  • Heptares Therapeutics Limited
  • Hyundai Pharmaceutical Co., Ltd.
  • Ildong Pharmaceutical Co., Ltd.
  • Immungenetics AG
  • ImStar Therapeutics Inc.
  • Integrative Research Laboratories Sweden AB
  • Intellect Neurosciences, Inc.
  • Intra-Cellular Therapies, Inc.
  • MediPost Co., Ltd.
  • Neuraltus Pharmaceuticals, Inc.
  • Neurimmune Holding AG
  • Neurodyn Inc.
  • Oryzon Genomics S.A.
  • Ovid Therapeutics Inc.
  • P2D Bioscience
  • Pacific Northwest Biotechnology, LLC
  • Pivot Pharmaceuticals Inc
  • Sinil Pharmaceutical Co., Ltd
  • Stelic Institute & Co., Inc.
  • 大日本住友製薬
  • Sylentis S.A.U.
  • TauRx Therapeutics Ltd.
  • WhanIn Pharmaceutical Co., Ltd.

認知症:治療薬の評価

  • 併用製品
  • 標的別
  • 作用機序別
  • 投与経路別
  • 分子タイプ別

薬剤のプロファイル

  • AADvac-1
  • 神経学向けmicroRNA阻害アンチセンスオリゴヌクレオチド
  • 脳虚血・認知症向け アンチセンスRNAiオリゴヌクレオチド
  • AVCRI-104P3
  • AZP-2006
  • BAN-0805
  • BI-409306
  • CB-2233
  • CB-8411
  • コリンアルホスセラートSR(徐放)
  • CPC-201
  • CPC-252
  • D-217
  • dehydroevodiamine hydrochloride
  • 認知症治療薬
  • 認知症向けc-MET作動薬
  • 認知症・認知機能障害向けマトリクス・メタロプロテイナーゼ阻害薬
  • DWJ-1365
  • E-2609
  • eltoprazine
  • encenicline hydrochloride
  • FRM-0334
  • GIBH-130
  • Gln-1062
  • GTC-6000
  • gugulipid
  • HOB-075
  • HTL-18318
  • IRL-752
  • ITI-007
  • KR-12
  • levetiracetam
  • LH-026
  • LUAF-20513
  • MM-201
  • 認知症・アルツハイマー病 向けモノクローナル抗体
  • 中枢神経系障害向けTau阻害モノクローナル抗体
  • NAT
  • nelotanserin
  • Neurostem
  • NI-205
  • NI-308
  • NNC-269100
  • NP-001
  • OG-635
  • ORY-2001
  • OV-201
  • P-003
  • PD-2015
  • PD-2016
  • PD-2024
  • PD-2244
  • PD-61W3
  • 脳障害・認知症向けBACE阻害剤
  • PST-900
  • RVT-101
  • salicylamine
  • SIN-1502
  • 神経変成疾患向けABC輸送体活性剤
  • 中枢神経・代謝障害向けLPL活性剤
  • 認知症向けグリコーゲン5阻害剤
  • 前頭側頭認知症向け小分子
  • 眼科学・中枢神経系障害向け小分子
  • 中枢神経系障害向けHGFR作動薬
  • レヴィー小体の認知症・パーキンソン病の認知症向けM1ムスカリン性アセチルコリン受容体作動薬
  • ALS・認知症・アルツハイマー病向けTANA阻害剤
  • SND-14
  • SYN-120
  • 神経疾患向けPACAP受容体活性およびVPAC1/VPAC2拮抗合成ペプチド
  • TAK-070
  • TauC-3
  • TPI-287
  • TRx-0237
  • TTT-3002
  • WIB-1001C
  • zonisamide

認知症治療薬:パイプライン製品の最新動向

認知症治療薬:開発が休止状態の製品

認知症治療薬:開発が中止された製品

認知症関連製品の開発のマイルストーン

  • 注目すべき最新動向・プレスリリース

付録

図表一覧

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC9056IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Dementia - Pipeline Review, H1 2017, provides an overview of the Dementia (Central Nervous System) pipeline landscape.

Dementia is the loss of mental functions such as thinking, memory, and reasoning that is severe enough to interfere with a person's daily functioning. Symptoms include memory loss, hallucinations, agitation, personality changes and difficulty with coordination and motor functions. Risk factors include age, smoking, obesity, high blood pressure, inflammation and cardiovascular diseases.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Dementia - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Dementia (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Dementia (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Dementia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 3, 11, 17, 33, 12 and 2 respectively. Similarly, the Universities portfolio in Phase I, Preclinical and Discovery stages comprises 1, 12 and 4 molecules, respectively.

Dementia (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Dementia (Central Nervous System).
  • The pipeline guide reviews pipeline therapeutics for Dementia (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Dementia (Central Nervous System) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Dementia (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Dementia (Central Nervous System)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Dementia (Central Nervous System).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Dementia (Central Nervous System) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
  • List of Tables
  • List of Figures
  • Introduction
  • Global Markets Direct Report Coverage
  • Dementia - Overview
  • Dementia - Therapeutics Development
  • Pipeline Overview
  • Pipeline by Companies
  • Pipeline by Universities/Institutes
  • Products under Development by Companies
  • Products under Development by Universities/Institutes
  • Dementia - Therapeutics Assessment
  • Assessment by Target
  • Assessment by Mechanism of Action
  • Assessment by Route of Administration
  • Assessment by Molecule Type
  • Dementia - Companies Involved in Therapeutics Development
  • Acorda Therapeutics Inc
  • Actinogen Medical Ltd
  • Adamas Pharmaceuticals Inc
  • AgeneBio Inc
  • Alector LLC
  • Allergan Plc
  • AlzProtect SAS
  • Amarantus Bioscience Holdings Inc
  • Anavex Life Sciences Corp
  • Asceneuron SA
  • Axon Neuroscience SE
  • Axovant Sciences Ltd.
  • BioArtic AB
  • Biogen Inc
  • Boehringer Ingelheim GmbH
  • Cortice Biosciences Inc
  • Daewoong Pharmaceutical Co Ltd
  • Echo Pharmaceuticals BV
  • Eisai Co Ltd
  • Eli Lilly and Company
  • H. Lundbeck A/S
  • Heptares Therapeutics Ltd
  • HSRx Group
  • Hyundai Pharmaceutical Co Ltd
  • Ildong Pharmaceutical Co Ltd
  • Immungenetics AG
  • ImStar Therapeutics Inc
  • Integrative Research Laboratories Sweden AB
  • Intellect Neurosciences Inc
  • INVENT Pharmaceuticals Inc
  • Ironwood Pharmaceuticals Inc
  • M3 Biotechnology Inc
  • MediPost Co Ltd
  • Neuraltus Pharmaceuticals Inc
  • Neurimmune Holding AG
  • Neuropore Therapies Inc
  • NsGene A/S
  • Oryzon Genomics SA
  • P2D Bioscience
  • Pacific Northwest Biotechnology LLC
  • Pharmasum Therapeutics AS
  • Prana Biotechnology Ltd
  • Sage Therapeutics Inc
  • Sinil Pharmaceutical Co Ltd
  • Stelic Institute & Co Inc
  • Stemedica Cell Technologies Inc
  • Sumitomo Dainippon Pharma Co Ltd
  • Suven Life Sciences Ltd
  • Sylentis SAU
  • TauRx Therapeutics Ltd
  • Voyager Therapeutics Inc
  • WhanIn Pharmaceutical Co Ltd
  • Zhejiang Hisun Pharmaceutical Co Ltd
  • Dementia - Drug Profiles
  • (donepezil hydrochloride + glycopyrrolate) - Drug Profile
  • (donepezil hydrochloride + memantine hydrochloride ER) - Drug Profile
  • (donepezil hydrochloride + solifenacin succinate) - Drug Profile
  • (glycopyrrolate + rivastigmine) - Drug Profile
  • AADvac-1 - Drug Profile
  • AD-35 - Drug Profile
  • ANAVEX-371 - Drug Profile
  • Antibody to Inhibit Tau Proteins for Corticobasal Degeneration - Drug Profile
  • Antisense RNAi Oligonucleotide for Cerebral Ischemia and Dementia - Drug Profile
  • ASN-561 - Drug Profile
  • AZP-2006 - Drug Profile
  • BAN-0805 - Drug Profile
  • BI-409306 - Drug Profile
  • CB-2233 - Drug Profile
  • CB-8411 - Drug Profile
  • Cell Therapy for Central Nervous System and Neurodegenerative Diseases - Drug Profile
  • choline alfoscerate SR - Drug Profile
  • CIDEM-162 - Drug Profile
  • D-217 - Drug Profile
  • dehydroevodiamine hydrochloride - Drug Profile
  • donepezil Depot - Drug Profile
  • donepezil Patch - Drug Profile
  • dronabinol - Drug Profile
  • Drugs for Dementia - Drug Profile
  • Drugs to Agonize Hepatocyte Growth Factor Receptor for Dementia - Drug Profile
  • Drugs to Inhibit Matrix Metalloproteinase for Dementia and Cognitive Impairment - Drug Profile
  • DWJ-1365 - Drug Profile
  • E-2027 - Drug Profile
  • E-2609 - Drug Profile
  • eltoprazine - Drug Profile
  • GIBH-130 - Drug Profile
  • Gln-1062 - Drug Profile
  • GTC-6000 - Drug Profile
  • gugulipid - Drug Profile
  • HOB-075 - Drug Profile
  • HTL-18318 - Drug Profile
  • intepirdine - Drug Profile
  • INV-331 - Drug Profile
  • IRL-752 - Drug Profile
  • IW-6463 - Drug Profile
  • landipirdine - Drug Profile
  • levetiracetam - Drug Profile
  • LUAF-20513 - Drug Profile
  • MM-201 - Drug Profile
  • Monoclonal Antibodies for Alzheimer's Disease and Vascular Dementia - Drug Profile
  • Monoclonal Antibodies to Inhibit SORT1 for Alzheimer's Disease and Dementia - Drug Profile
  • Monoclonal Antibodies to Inhibit Tau for CNS Disorders - Drug Profile
  • Monoclonal Antibody to Inhibit Tau for Central Nervous System Disorders - Drug Profile
  • monosodium luminol - Drug Profile
  • NAT - Drug Profile
  • nelotanserin - Drug Profile
  • Neurostem - Drug Profile
  • NI-205 - Drug Profile
  • NI-308 - Drug Profile
  • NNC-269100 - Drug Profile
  • NP-001 - Drug Profile
  • NPT100-18A - Drug Profile
  • NXN-413 - Drug Profile
  • NXN-613 - Drug Profile
  • ORY-2001 - Drug Profile
  • PAM-43 - Drug Profile
  • PBT-434 - Drug Profile
  • PD-2015 - Drug Profile
  • PD-2024 - Drug Profile
  • PD-2244 - Drug Profile
  • Peptide to Inhibit BACE for Cerebropathy and Dementia - Drug Profile
  • PST-900 - Drug Profile
  • rivastigmine - Drug Profile
  • salicylamine - Drug Profile
  • SGE-201 - Drug Profile
  • SIN-1502 - Drug Profile
  • Small Molecule for Vascular Dementia - Drug Profile
  • Small Molecule to Activate ABC Transporter for Neurodegeneration Disorders - Drug Profile
  • Small Molecule to Activate LPL for CNS and Metabolic Disorders - Drug Profile
  • Small Molecule to Agonize Dopamine D1 Receptor for Dementia Associated with Alzheimer's Disease - Drug Profile
  • Small Molecule to Inhibit Glycogene 5 for Dementia - Drug Profile
  • Small Molecule to Inhibit TNF-Alpha for CNS Disorders - Drug Profile
  • Small Molecules for Ophthalmology and CNS Disorders - Drug Profile
  • Small Molecules to Agonize HGFR for CNS Disorders - Drug Profile
  • Small Molecules to Agonize M1 Muscarinic Acetylcholine Receptor for Central Nervous System - Drug Profile
  • Small Molecules to Inhibit TANA for ALS, Alzheimer's Disease and Dementia - Drug Profile
  • SND-14 - Drug Profile
  • Stem Cell Therapy for Dementia Associated with Alzheimer's Disease - Drug Profile
  • SUVNI-1307014 - Drug Profile
  • SUVNI-1312004 - Drug Profile
  • Synthetic Peptides to Activate PACAP Receptor and Antagonize VPAC1, VPAC2 for Neurological Disorders - Drug Profile
  • TAK-070 - Drug Profile
  • TauC-3 - Drug Profile
  • tolfenamic acid - Drug Profile
  • TPI-287 - Drug Profile
  • TRx-0237 - Drug Profile
  • UE-2343 - Drug Profile
  • VYTAU-01 - Drug Profile
  • WIB-1001C - Drug Profile
  • zonisamide - Drug Profile
  • Dementia - Dormant Projects
  • Dementia - Discontinued Products
  • Dementia - Product Development Milestones
  • Featured News & Press Releases
  • Appendix
  • Methodology
  • Coverage
  • Secondary Research
  • Primary Research
  • Expert Panel Validation
  • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development for Dementia, H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017
  • Number of Products under Development by Companies, H1 2017 (Contd..2), H1 2017
  • Number of Products under Development by Companies, H1 2017 (Contd..3), H1 2017
  • Number of Products under Development by Universities/Institutes, H1 2017
  • Products under Development by Companies, H1 2017
  • Products under Development by Companies, H1 2017 (Contd..1), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..2), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..3), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..4), H1 2017
  • Products under Development by Universities/Institutes, H1 2017
  • Number of Products by Stage and Target, H1 2017
  • Number of Products by Stage and Target, H1 2017 (Contd..1), H1 2017
  • Number of Products by Stage and Target, H1 2017 (Contd..2), H1 2017
  • Number of Products by Stage and Mechanism of Action, H1 2017
  • Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..1), H1 2017
  • Number of Products by Stage and Route of Administration, H1 2017
  • Number of Products by Stage and Molecule Type, H1 2017
  • Dementia - Pipeline by Acorda Therapeutics Inc, H1 2017
  • Dementia - Pipeline by Actinogen Medical Ltd, H1 2017
  • Dementia - Pipeline by Adamas Pharmaceuticals Inc, H1 2017
  • Dementia - Pipeline by AgeneBio Inc, H1 2017
  • Dementia - Pipeline by Alector LLC, H1 2017
  • Dementia - Pipeline by Allergan Plc, H1 2017
  • Dementia - Pipeline by AlzProtect SAS, H1 2017
  • Dementia - Pipeline by Amarantus Bioscience Holdings Inc, H1 2017
  • Dementia - Pipeline by Anavex Life Sciences Corp, H1 2017
  • Dementia - Pipeline by Asceneuron SA, H1 2017
  • Dementia - Pipeline by Axon Neuroscience SE, H1 2017
  • Dementia - Pipeline by Axovant Sciences Ltd., H1 2017
  • Dementia - Pipeline by BioArtic AB, H1 2017
  • Dementia - Pipeline by Biogen Inc, H1 2017
  • Dementia - Pipeline by Boehringer Ingelheim GmbH, H1 2017
  • Dementia - Pipeline by Cortice Biosciences Inc, H1 2017
  • Dementia - Pipeline by Daewoong Pharmaceutical Co Ltd, H1 2017
  • Dementia - Pipeline by Echo Pharmaceuticals BV, H1 2017
  • Dementia - Pipeline by Eisai Co Ltd, H1 2017
  • Dementia - Pipeline by Eli Lilly and Company, H1 2017
  • Dementia - Pipeline by H. Lundbeck A/S, H1 2017
  • Dementia - Pipeline by Heptares Therapeutics Ltd, H1 2017
  • Dementia - Pipeline by HSRx Group, H1 2017
  • Dementia - Pipeline by Hyundai Pharmaceutical Co Ltd, H1 2017
  • Dementia - Pipeline by Ildong Pharmaceutical Co Ltd, H1 2017
  • Dementia - Pipeline by Immungenetics AG, H1 2017
  • Dementia - Pipeline by ImStar Therapeutics Inc, H1 2017
  • Dementia - Pipeline by Integrative Research Laboratories Sweden AB, H1 2017
  • Dementia - Pipeline by Intellect Neurosciences Inc, H1 2017
  • Dementia - Pipeline by INVENT Pharmaceuticals Inc, H1 2017
  • Dementia - Pipeline by Ironwood Pharmaceuticals Inc, H1 2017
  • Dementia - Pipeline by M3 Biotechnology Inc, H1 2017
  • Dementia - Pipeline by MediPost Co Ltd, H1 2017
  • Dementia - Pipeline by Neuraltus Pharmaceuticals Inc, H1 2017
  • Dementia - Pipeline by Neurimmune Holding AG, H1 2017
  • Dementia - Pipeline by Neuropore Therapies Inc, H1 2017
  • Dementia - Pipeline by NsGene A/S, H1 2017
  • Dementia - Pipeline by Oryzon Genomics SA, H1 2017
  • Dementia - Pipeline by P2D Bioscience, H1 2017
  • Dementia - Pipeline by Pacific Northwest Biotechnology LLC, H1 2017
  • Dementia - Pipeline by Pharmasum Therapeutics AS, H1 2017
  • Dementia - Pipeline by Prana Biotechnology Ltd, H1 2017
  • Dementia - Pipeline by Sage Therapeutics Inc, H1 2017
  • Dementia - Pipeline by Sinil Pharmaceutical Co Ltd, H1 2017
  • Dementia - Pipeline by Stelic Institute & Co Inc, H1 2017
  • Dementia - Pipeline by Stemedica Cell Technologies Inc, H1 2017
  • Dementia - Pipeline by Sumitomo Dainippon Pharma Co Ltd, H1 2017
  • Dementia - Pipeline by Suven Life Sciences Ltd, H1 2017
  • Dementia - Pipeline by Sylentis SAU, H1 2017
  • Dementia - Pipeline by TauRx Therapeutics Ltd, H1 2017
  • Dementia - Pipeline by Voyager Therapeutics Inc, H1 2017
  • Dementia - Pipeline by WhanIn Pharmaceutical Co Ltd, H1 2017
  • Dementia - Pipeline by Zhejiang Hisun Pharmaceutical Co Ltd, H1 2017
  • Dementia - Dormant Projects, H1 2017
  • Dementia - Dormant Projects, H1 2017 (Contd..1), H1 2017
  • Dementia - Dormant Projects, H1 2017 (Contd..2), H1 2017
  • Dementia - Dormant Projects, H1 2017 (Contd..3), H1 2017
  • Dementia - Discontinued Products, H1 2017

List of Figures

  • Number of Products under Development for Dementia, H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Number of Products under Development by Universities/Institutes, H1 2017
  • Number of Products by Top 10 Targets, H1 2017
  • Number of Products by Stage and Top 10 Targets, H1 2017
  • Number of Products by Top 10 Mechanism of Actions, H1 2017
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017
  • Number of Products by Routes of Administration, H1 2017
  • Number of Products by Stage and Routes of Administration, H1 2017
  • Number of Products by Top 10 Molecule Types, H1 2017
  • Number of Products by Stage and Top 10 Molecule Types, H1 2017
Back to Top